Lintuzumab actinium AC-225
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Lintuzumab actinium AC-225
- 225ac hum195
- 225ac lintuzumab
- 225ac-hum195
- 225ac-lintuzumab
- actimab a
- Actimab-a
- Actinio (225ac) lintuzumab satetraxetan
- actinio 225ac lintuzumab satetraxetan
- Actinium (225ac) lintuzumab satetraxetan
- Actinium (225Ac) rhPSMA-10.1
- Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])
- actinium 225 labeled humanized anti cd33 monoclonal antibody hum195
- actinium 225ac lintuzumab satetraxetan
- actinium 225ac rhpsma 10 1
- actinium ac 225 lintuzumab
- Actinium ac 225 lintuzumab
- Actinium ac-225 lintuzumab
- Actinium-225-labeled humanized anti-cd33 monoclonal antibody hum195
- hum 195 ac 225
- Hum-195 ac-225
- lintuzumab actinium ac 225
- Lintuzumab actinium ac-225
- lintuzumab satetraxetan ac 225
- Lintuzumab satetraxetan ac-225
- sgn 33 ac 225
And 1 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL4297554
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -mab; -mab
- Condition identifier
- EFO_0000198
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000222
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005170
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015667
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (31)
- A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors
- A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
- A Phase 1 Study of [225Ac]-FPI-1434 Injection
- A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
- A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
- A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens
- A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
- A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
- A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
- A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
- ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer
- First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
- Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
In development for (3)
- Acute myeloid leukemia by FAB classification Phase 2
- Myelodysplastic syndrome Phase 2
- Plasma cell myeloma Phase 1